Publications
2024
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Lim, Y. J., Ward, V., Brown, A., Phillips, E., Kronsteiner, B., Malone, T., . . . Pettitt, A. (2024). Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.. British journal of haematology, 205(2), 440-451. doi:10.1111/bjh.19562
2023
Deep Immune Profiling Identifies Novel T-Cell Subpopulations That Influence Specific Clinical Outcomes in Chronic Lymphocytic Leukaemia (CLL)
Lim, Y. J., Duckworth, A., Clarke, K., Kennedy, P., Oates, M., Gornall, M., . . . Pettitt, A. (2023). Deep Immune Profiling Identifies Novel T-Cell Subpopulations That Influence Specific Clinical Outcomes in Chronic Lymphocytic Leukaemia (CLL). Blood, 142(Supplement 1), 4626. doi:10.1182/blood-2023-185091
High Dimensional Detection of Non-Malignant B-Cells and Its Clinical Implications in Patients with Chronic Lymphocytic Leukaemia (CLL) Undergoing Frontline Therapy
Lim, Y. J., Duckworth, A., Clarke, K., Oates, M., Gornall, M., Kalakonda, N., . . . Pettitt, A. (2023). High Dimensional Detection of Non-Malignant B-Cells and Its Clinical Implications in Patients with Chronic Lymphocytic Leukaemia (CLL) Undergoing Frontline Therapy. Blood, 142(Supplement 1), 1894. doi:10.1182/blood-2023-185018
Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL)
Lim, Y. J., Duckworth, A., Clarke, K., Oates, M., Gornall, M., Kalakonda, N., . . . Pettitt, A. (2023). Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL). Blood, 142(Supplement 1), 1455. doi:10.1182/blood-2023-185063
P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY
Jer Lim, Y., Ward, V., Farrell, L., Naisbitt, D., Brown, A., Phillips, E., . . . Pettitt, A. (n.d.). P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY. HemaSphere, 7(S3), e49729ac. doi:10.1097/01.hs9.0000971276.49729.ac
2022
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
Robbe, P., Ridout, K. E., Vavoulis, D. V., Dreau, H., Kinnersley, B., Denny, N., . . . Schuh, A. (2022). Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. NATURE GENETICS, 54(11), 1675-+. doi:10.1038/s41588-022-01211-y
2021
Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells.
Eagle, G. L., Herbert, J. M. J., Zhuang, J., Oates, M., Khan, U. T., Kitteringham, N. R., . . . Falciani, F. (2021). Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells.. Scientific Reports, 11(1), 2932. doi:10.1038/s41598-021-82609-2
Clopidogrel resistance in stroke patients (The CRISP Trial)
Qazi,, E., Zaidi, S. A. H., O Owojori, O., Bonnett, L. J., Fitzsimmons, P. R., Sharma, N., . . . Manoj, A. (n.d.). Clopidogrel resistance in stroke patients (The CRISP Trial). Journal of Neurology & Stroke, 11(1), 1-5. doi:10.15406/jnsk.2021.11.00444
Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia
Mohammad, I., Lin, K., Oates, M., Khan, U., Burger, J., Pettitt, A., & Zhuang, J. (n.d.). Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia. Leukemia and Lymphoma. doi:10.1080/10428194.2020.1811274
2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.. Haematologica, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial. HAEMATOLOGICA, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805
Clopidogrel resistance in stroke patients (The CRISP Trial)
Qazi,, E., AH Zaidi, S., Owojori, O. O., Bonnett, L. J., Fitzsimmons, P. R., Sharma, N., . . . Manoj, A. (n.d.). Clopidogrel resistance in stroke patients (The CRISP Trial). Journal of Neurology & Stroke, 11(1), 1-5. doi:10.15406/jnsk.2020.11.00444
Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification
Ridout, K., Robbe, P., Cavalieri, D., Alsolami, R., Antoniou, P., Appleby, N., . . . Schuh, A. (2020). Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 167-168). Retrieved from https://www.webofscience.com/
Deep phenotypic analysis of mutated and unmutated CLL cells by mass cytometry
Jawad, M., Sophie, A., Duckworth, A., Karpha, I., Bithell, J., Oates, M., . . . Slupsky, J. (2020). Deep phenotypic analysis of mutated and unmutated CLL cells by mass cytometry. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 177-179). Retrieved from https://www.webofscience.com/
Resistance to venetoclax-induced apoptosis of CLL cells due to CD40 stimulation can be reversed by BCL-XL inhibition
Zhuang, J., Luckett, T., Cheng, X., Oates, M., Varadarajan, S., & Pettitt, A. (2020). Resistance to venetoclax-induced apoptosis of CLL cells due to CD40 stimulation can be reversed by BCL-XL inhibition. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 234-235). Retrieved from https://www.webofscience.com/
2019
BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL
Pettitt, A., Kalakonda, N., Cicconi, S., Murphy, C., Menon, G., Coupland, S. E., . . . Hillmen, P. (2019). BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL. In Hematological Oncology Vol. 37 (pp. 217-218). Wiley. doi:10.1002/hon.32_2630
NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA
Pettitt, A. R., Barrington, S., Kalakonda, N., Khan, U. T., Jackson, R., Carruthers, S., . . . Trotman, J. (2019). NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA. Hematological Oncology, 37(S2), 67-68. doi:10.1002/hon.35_2629
2018
Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification
Ridout, K. E., Robbe, P., Cavalieri, D., Becq, J., He, M., Clifford, R., . . . Schuh, A. (2018). Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-115935
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.
Alharthi, A., Beck, D., Howard, D. R., Hillmen, P., Oates, M., Pettitt, A., & Wagner, S. D. (2018). An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.. BMC research notes, 11(1), 280. doi:10.1186/s13104-018-3391-9
Whole genome sequencing in the clinic identifies CLL patients with high risk of relapse: pilot study for the 100,000 Genomes Project
Robbe, P., Ridout, K., Becq, J., He, M., Clifford, R., Burns, A., . . . Schuh, A. (2018). Whole genome sequencing in the clinic identifies CLL patients with high risk of relapse: pilot study for the 100,000 Genomes Project. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 28). Retrieved from https://www.webofscience.com/
2017
Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples
Eagle, G., Zhuang, J., Oates, M., Kitteringham, N., Herbert, J., Falciani, F., . . . Hillmen, P. (2017). Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 100-101). Retrieved from https://www.webofscience.com/
Use of differentiated THP. 1 cells to mimic nurse-like cells for its pro-survival effect on chronic lymphocytic leukaemia cells
Mohammad, I. S., Zhuang, J., Pettitt, A., Oates, M., & Lin, K. (2017). Use of differentiated THP. 1 cells to mimic nurse-like cells for its pro-survival effect on chronic lymphocytic leukaemia cells. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 102-104). Retrieved from https://www.webofscience.com/
Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia
Chapman, E. A., Oates, M., Mohammad, I. S., Davies, B. R., Stockman, P. K., Zhuang, J., & Pettitt, A. R. (2017). Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia. Oncotarget, 8(61), 102948-102964. doi:10.18632/oncotarget.22292
EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.
Pettitt, A. R., Kalakonda, N., Polydoros, F., Bickerstaff, M., Menon, G., Coupland, S. E., . . . Hillmen, P. (2017). EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.. Hematological Oncology, 35(S2), 88-89. doi:10.1002/hon.2437_77
Optimising Technical Protocols to Detect AID Expression in Archived FFPE Samples of Patients with Follicular Lymphoma
Alishlash, O., Lin, K., Coupland, S., Oates, M., Kalirai, H., & Pettitt, A. (2017). Optimising Technical Protocols to Detect AID Expression in Archived FFPE Samples of Patients with Follicular Lymphoma. In JOURNAL OF PATHOLOGY Vol. 241 (pp. S11). Retrieved from https://www.webofscience.com/
2016
Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot
Robbe, P., Ridout, K., Becq, J., He, M., Clifford, R., Alsolami, R., . . . Schuh, A. (2016). Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.2022.2022
FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB, DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK CLL (ORIGINAL PROTOCOL)
Pettitt, A. R., Polydoros, F., Dodd, J., Oates, M., Lin, K., Kalakonda, N., . . . Hillmen, P. (2016). FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB, DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK CLL (ORIGINAL PROTOCOL). In HAEMATOLOGICA Vol. 101 (pp. 726). Retrieved from https://www.webofscience.com/
LINKING PROTEOME AND GENOME FOR BIOMARKER DISCOVERY IN CLL-ESTABLISHMENT OF A CLL PROTEIN DATABASE
Eagle, G. L., Zhuang, J., Jenkins, R., Kitteringham, N., Oates, M., Park, K., . . . Pettitt, A. (2016). LINKING PROTEOME AND GENOME FOR BIOMARKER DISCOVERY IN CLL-ESTABLISHMENT OF A CLL PROTEIN DATABASE. In HAEMATOLOGICA Vol. 101 (pp. 420-421). Retrieved from https://www.webofscience.com/
Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus (vol 10, e0142379, 2015)
Hargreaves, C. E., Iriyama, C., Rose-Zerilli, M. J. J., Nagelkerke, S. Q., Hussain, K., Ganderton, R., . . . Strefford, J. C. (2016). Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus (vol 10, e0142379, 2015). PLOS ONE, 11(3). doi:10.1371/journal.pone.0145040
2015
Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus
Hargreaves, C. E., Iriyama, C., Rose-Zerilli, M. J. J., Nagelkerke, S. Q., Hussain, K., Ganderton, R., . . . Strefford, J. C. (2015). Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus. PLOS ONE, 10(11). doi:10.1371/journal.pone.0142379
Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia
Eagle, G., Zhuang, J., Jenkins, R., Till, K., Jithesh, P., Lin, K., . . . Pettitt, A. (2015). Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia. Molecular and Cellular Proteomics, 14(4), 933-945. doi:10.1074/mcp.M114.044479
2014
Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells.
Primo, D., De la Serna, J., Martinez, J., Gonzalez, M., Lopez, J., Barez, A., . . . Hernandez, P. (2014). Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells.. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Genomic Dissection of the Fcγ Receptor Region in the Context of Monoclonal Antibody Therapy
Hargreaves, C., Iriyama, C., Rose-Zerilli, M. J. J., Lee, C., Potter, K., Ganderton, R., . . . Strefford, J. C. (2014). Genomic Dissection of the Fcγ Receptor Region in the Context of Monoclonal Antibody Therapy. BLOOD, 124(21). Retrieved from https://www.webofscience.com/
The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays
Knight, S. J. L., Clifford, R., Robbe, P., Ramos, S. D. C., Burns, A., Timbs, A. T., . . . Shuh, A. (2014). The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays. BLOOD, 124(21). Retrieved from https://www.webofscience.com/
Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia
Eagle, G. L., Jenkins, R. E., Till, K. J., Puthen, J., Lin, K., Johnson, G. G., . . . Pettitt, A. R. (2014). Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials
Clifford, R. M., Robbe, P., Weller, S., Timbs, A. T., Titsias, M., Burns, A., . . . Schuh, A. (2014). Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Selective IAP inhibition results in sensitization of unstimulated but not CD40‐stimulated chronic lymphocytic leukaemia cells to TRAIL‐induced apoptosis
Zhuang, J., Laing, N., Oates, M., Lin, K., Johnson, G., & Pettitt, A. R. (2014). Selective IAP inhibition results in sensitization of unstimulated but not CD40‐stimulated chronic lymphocytic leukaemia cells to TRAIL‐induced apoptosis. Pharmacology Research & Perspectives, 2(6). doi:10.1002/prp2.81
Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia
Lin, K., Farahani, M., Yang, Y., Johnson, G. G., Oates, M., Atherton, M., . . . Pettitt, A. R. (2014). Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 167(3), 346-355. doi:10.1111/bjh.13043
Abstract T P344: Clopidogrel Resistance in Stroke Patients (The CRISP Trial)
Manoj, A. L., Fitzsimmons, P. R., Sharma, N., Menezes, B., Thachil, J., Greenhalf, W., . . . Cox, P. (2014). Abstract T P344: Clopidogrel Resistance in Stroke Patients (The CRISP Trial). Stroke, 45(suppl_1). doi:10.1161/str.45.suppl_1.tp344
2013
<i>CYP2B6</i>*<i>6</i> is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia
Johnson, G. G., Lin, K., Cox, T. F., Oates, M., Sibson, D. R., Eccles, R., . . . Pettitt, A. R. (2013). <i>CYP2B6</i>*<i>6</i> is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. BLOOD, 122(26), 4253-4258. doi:10.1182/blood-2013-07-516666
High expression of <i>TP53</i> mRNA is associated with allelic loss of 13q14 and short survival in chronic lymphocytic leukaemia
Lin, K., Johnson, G. G., Farahani, M., Oates, M., Atherton, M., Douglas, A., . . . Pettitt, A. R. (2013). High expression of <i>TP53</i> mRNA is associated with allelic loss of 13q14 and short survival in chronic lymphocytic leukaemia. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 161 (pp. 43-44). Retrieved from https://www.webofscience.com/
Pharmacogenetic analysis of CYP2B6 in the LRF CLL4 trial: the*6 allelic variant is associated with inferior efficacy following fludarabine plus cyclophosphamide
Johnson, G. G., Lin, K., Cox, T., Oates, M., Sibson, D. R., Eccles, R., . . . Pettitt, A. R. (2013). Pharmacogenetic analysis of CYP2B6 in the LRF CLL4 trial: the*6 allelic variant is associated with inferior efficacy following fludarabine plus cyclophosphamide. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 161 (pp. 19). Retrieved from https://www.webofscience.com/
The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p
Lin, K., Lane, B., Carter, A., Johnson, G. G., Onwuazor, O., Oates, M., . . . Pettitt, A. R. (2013). The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p. BRITISH JOURNAL OF HAEMATOLOGY, 160(1), 53-62. doi:10.1111/bjh.12092
2012
Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak
Melarangi, T., Zhuang, J., Lin, K., Rockliffe, N., Bosanquet, A. G., Oates, M., . . . Pettitt, A. R. (2012). Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak. CELL DEATH & DISEASE, 3. doi:10.1038/cddis.2012.102
Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration
Lin, K., Adamson, J., Johnson, G. G., Carter, A., Oates, M., Wade, R., . . . Pettitt, A. R. (2012). Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration. CLINICAL CANCER RESEARCH, 18(15), 4191-4200. doi:10.1158/1078-0432.CCR-11-2936
Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial
Pettitt, A. R., Jackson, R., Carruthers, S., Dodd, J., Dodd, S., Oates, M., . . . Hillmen, P. (2012). Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial. JOURNAL OF CLINICAL ONCOLOGY, 30(14), 1647-1655. doi:10.1200/JCO.2011.35.9695
The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes in chromosome 17p
Lin, K., Lane, B., Carter, A., Johnson, G. G., Onwuazor, O., Oates, M., . . . Pettitt, A. R. (2012). The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes in chromosome 17p. British Journal of Haematology.
2007
The angiogenic potential of three-dimensional open porous synthetic matrix materials
Oates, M., Chen, R., Duncan, M., & Hunt, J. A. (2007). The angiogenic potential of three-dimensional open porous synthetic matrix materials. BIOMATERIALS, 28(25), 3679-3686. doi:10.1016/j.biomaterials.2007.04.042
2006
Assessing the intrinsic angiogenic potential of biomaterials and scaffolds using image analysis and chorioallantoic membrane (CAM) assay
Oates, M., Andrews, K., & Hunt, J. A. (2006). Assessing the intrinsic angiogenic potential of biomaterials and scaffolds using image analysis and chorioallantoic membrane (CAM) assay. In TISSUE ENGINEERING Vol. 12 (pp. 985). Retrieved from https://www.webofscience.com/
Human mesenchymal stem cell differentiation on modified thin polymer films in a hypoxic microfluidic bioreactor: An experimental and computational modelling study
Curran, S. J., Chen, R., Oates, M., & Hunt, J. A. (2006). Human mesenchymal stem cell differentiation on modified thin polymer films in a hypoxic microfluidic bioreactor: An experimental and computational modelling study. TISSUE ENGINEERING, 12(4), 1024. Retrieved from https://www.webofscience.com/
2005
Cartilage tissue engineering using modified poly-(L-lactide) microspheres in an intermittent stirred flow bioreactor under hypoxic conditions
Curran, S. J., Chen, R., Oates, M., Curran, J., & Hunt, J. A. (2005). Cartilage tissue engineering using modified poly-(L-lactide) microspheres in an intermittent stirred flow bioreactor under hypoxic conditions. European Cells and Materials, 10(SUPPL.2), 30.
2004
Quantification of endothelial cell sprouting within gel/ scaffold tissue engineering devices
Oates, M., Hunt, J. A., & Williams, D. F. (2004). Quantification of endothelial cell sprouting within gel/ scaffold tissue engineering devices. In Transactions - 7th World Biomaterials Congress (pp. 1729).
1999
07 The differential regulation of the endothelial protein C receptor (EPCR) and thrombomodulin by inflammatory cytokines
Oates, M., Perez-Casal, M. M., Chen, H. J., & Toh, C. H. (1999). 07 The differential regulation of the endothelial protein C receptor (EPCR) and thrombomodulin by inflammatory cytokines. Blood Coagulation & Fibrinolysis, 10(8), 532. doi:10.1097/00001721-199912000-00019
Interleukin-1β down-regulates endothelial cell protein C receptor expression.
Oates, M., Perez-Casal, M., Chen, H. J., & Toh, C. H. (1999). Interleukin-1β down-regulates endothelial cell protein C receptor expression.. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 105 (pp. 28). Retrieved from https://www.webofscience.com/
The enhanced shedding of the endothelial protein C receptor by interleukin-1β is mediated by metalloproteinases.
Oates, M., Chen, H., & Toh, C. H. (1999). The enhanced shedding of the endothelial protein C receptor by interleukin-1β is mediated by metalloproteinases.. In BLOOD Vol. 94 (pp. 75B). Retrieved from https://www.webofscience.com/
The role of focal adhesion kinase (FAK) and the protein tyrosine phosphatase SHP-2 in α4β1/α5β1 and αvβ3 integrin-mediated adhesion and motility of hairy cells.
Baker, P. K., Burthem, J., Kamiguti, A. S., Oates, M., Cawley, J. C., & Zuzel, M. (1999). The role of focal adhesion kinase (FAK) and the protein tyrosine phosphatase SHP-2 in α4β1/α5β1 and αvβ3 integrin-mediated adhesion and motility of hairy cells.. In BLOOD Vol. 94 (pp. 548A). Retrieved from https://www.webofscience.com/
1997
A cell model for studies on the function of the endothelial protein C receptor
Oates, M., Chen, H. J., & Toh, C. H. (1997). A cell model for studies on the function of the endothelial protein C receptor. Blood Coagulation & Fibrinolysis, 8(7), 463. doi:10.1097/00001721-199710000-00024